A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine
(2013)
Journal Article
Walsby, E., Pratt, G., Shao, H., Abbas, A. Y., Fischer, P., Bradshaw, T. D., Brennan, P., Fegan, C., Wang, S., & Pepper, C. (2013). A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget, 5, 375-385
Cdk9 is a key elongation factor for RNA transcription and functions by phosphorylating the C-terminal domain of RNA polymerase II. Here we present direct evidence that cdk9 is important for cancer cell survival and describe the characterization of th... Read More about A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine.